推荐产品
![O,O′-双[2-(N-琥珀酰亚胺-琥珀酰氨基)乙基]聚乙二醇 2,000](/deepweb/assets/sigmaaldrich/product/structures/161/408/20f7ade0-3e2e-4861-ae89-3d81c050059a/640/20f7ade0-3e2e-4861-ae89-3d81c050059a.png)
![O-(3-羧丙基)-O′-[2-(3-巯基丙酰氨基)乙基]-聚乙二醇 Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
形狀
lumps
分子量
average Mn 10,000
反應適用性
reagent type: cross-linking reagent
Ω-end
NHS ester
α-end
NHS ester
儲存溫度
−20°C
正在寻找类似产品? 访问 产品对比指南
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
商品
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门